A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer

Inclusion criteria

• ✓. Ability to understand and sign a written informed consent documen；
• ✓. At the date of signing ICF, 18 \~70 years old, male or female；
• ✓. Histopathological confirmed advanced or metastatic pancreatic cancer patients who have failed to standard treatment or intolerance with standard treatment；
• ✓. Positive mesothelin expression;
• ✓. At least one measurable lesion at baseline per RECIST version 1.1；
• ✓. The expected survival time is more than 12 weeks;
• ✓. ECOG 0-1 points;
• ✓. Adequate organ functions.